Sonova Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SONVF research report →
Price Chart
About the company
Headquartered in Stäfa, Switzerland, Sonova Holding AG is a leading provider of innovative hearing care solutions for both adults and children. The company's operations are divided into two primary segments: Hearing Instruments and Cochlear Implants. Sonova's extensive offerings include advanced wireless communication devices, rechargeable hearing aids, wireless headsets, speech-enhanced hearables, premium audiophile headphones, microphones, and wireless transmission systems, alongside comprehensive audiological care services.
- CEO
- Eric Alain Bernard
- IPO
- 2007
- Employees
- 18,447
- HQ
- Stäfa, ZH, CH
Get TickerSpark's AI analysis on SONVF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.01B
- P/E
- 35.20
- Fwd P/E
- 29.62
- PEG
- -6.84
- P/S
- 4.79
- P/B
- 6.23
- EV/EBITDA
- 17.34
- Div Yield
- 1.61%
- Gross Margin
- 75.93%
- Op Margin
- 21.92%
- Net Margin
- 13.61%
- ROE
- 18.27%
- ROIC
- 13.71%
Latest fiscal year · YoY change
- Revenue
- $3.61B-6.5%
- Gross Profit
- $2.66B-4.5%
- Op Income
- $675.90M
- Net Income
- $430.60M-20.3%
- EPS
- $7.19-20.7%
- OCF Growth
- -13.6%
- FCF Growth
- -7.9%
- 52W High
- $356.00
- 52W Low
- $208.55
- 50D MA
- $317.64
- 200D MA
- $269.37
- Beta
- 1.10
- RSI (14)
- 52
- Avg Volume
- 59
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sonova delivered a strong first half with broad-based growth, rising margins and cash flow, and raised full-year sales and EBIT guidance as EON and other launches gained traction.· November 12, 2026
- Group sales rose 7.5% in local currencies to CHF 1.8 billion, with core EBIT up 22.9% to CHF 384 million and core EPS up 38% to CHF 5.37.
- Core gross margin improved to 74.7% and core EBIT margin to 20.9%, helped by volume, pricing and better operating execution.
- Wholesale grew 11% and hearing instruments grew 9%; management said Sonova has now posted 11 consecutive quarters of market share gains.
- Asia Pacific was the fastest-growing region at 11.4%, with double-digit growth in hearing instruments and profitable expansion in China, Japan and Australia/New Zealand.
- Management raised full-year guidance to 6% to 8% sales growth and 10% to 13% core EBIT growth, while signaling low-double-digit CHF million of extra strategic spending in H2.
Reported first-half group sales were CHF 1.8 billion, up 7.5% in local currencies and 6.7% in Swiss francs. Core gross profit was CHF 1.4 billion and core gross margin was 74.7%, about 230 basis points higher in local currency year over year. Core EBIT was CHF 384 million, up 22.9%, with core EBIT margin at 20.9% versus 18.4% last year; core EPS rose 38% to CHF 5.37. Operating free cash flow increased to CHF 287 million from CHF 90 million, and free cash flow rose to CHF 266 million from CHF 60 million. Reported EPS was CHF 5.18, or CHF 4.22 including discontinued operations. For the full year, Sonova now expects sales growth of 6% to 8% and core EBIT growth of 10% to 13%; it also raised its market growth assumption to 3% to 5% and expects currency translation to be broadly neutral.
Eric Bernard framed the quarter as proof that Sonova’s March strategy is now showing up in execution, citing innovation, market-share gains and better operations. He emphasized EON’s strong early reception, improved fulfillment versus the prior launch cycle, and accelerating profitably in Asia. His tone was confident but still candid about underperforming cochlear implants, saying CI “needs to improve” and that Integro is an important first step, not a finished solution.
Elodie Carr-Cingari highlighted disciplined profit conversion and cash generation, noting 7.5% sales growth, CHF 384 million of core EBIT, CHF 378 million of operating cash flow and CHF 287 million of operating free cash flow. She attributed the margin improvement to higher volumes, positive ASPs in wholesale and retail, and the absence of prior-year temporary manufacturing/logistics costs, while also flagging higher R&D, sales and marketing, and G&A spend to support growth. She said Sonova will step up strategic investments by a low-double-digit CHF million amount in H2, remains on track for CHF 35 million to CHF 40 million of noncore costs for the full year, and still expects to deploy around CHF 80 million to CHF 100 million annually in bolt-on M&A.
Analysts focused on what is driving the guidance raise, whether higher growth reflects market strength versus share gains, and how much H2 EBIT is being weighed by strategic investment timing. Management said the market has been stronger than expected, but reiterated that Sonova also expects continued share gains and is deliberately accelerating R&D, operations and digital investments in H2. On M&A and capital return, management said the pipeline is active and that the company is holding back on a share buyback for this fiscal year. Questions also probed wholesale durability, EON adoption, U.S. managed care and Costco-like retail account dynamics; management said wholesale growth was steady through the half, EON is being very well received, managed care is more normalized than transformative, and Sonova has reached fair share in its large U.S. retail account.
The strongest bull case from the call is that Sonova is growing faster than the market while expanding margins and cash flow at the same time. Management sounded increasingly confident that EON, Virto R and other launches are translating into durable share gains, and Asia Pacific is emerging as a meaningful growth engine. The raised guidance suggests the company believes it can keep outgrowing the market even while reinvesting in future products and operations.
The main risks discussed were the still-weak cochlear implant business, uncertainty around U.S. approval timing for Integro, and the possibility that some of the market strength in H1 was boosted by launch-related stocking. Management also said strategic spending will ramp in H2, which could pressure near-term EBIT growth despite better sales. In retail, the U.S. was described as slower than some other regions, and management acknowledged that a price barrier still limits uptake of the highest-end Sphere products.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 82.1%
- Shares Outstanding
- 59.54M
- Float Shares
- 48.88M
Our SONVF coverage
Recent articles, reports, and earnings notes.
No research on SONVF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SONVF report →Switzerland's Sonova raises full-year forecasts on market-share gains, product launches
reuters.com · Nov 12
Sonova unveils new AI-powered hearing-aid platform to support growth targets
reuters.com · Aug 24
Sonova Holding AG (SONVY) Q4 2026 Earnings Call Transcript
seekingalpha.com · May 18
Sonova Holding AG (SONVY) Discusses Refreshed Strategy and Vision for Next Phase of Growth Transcript
seekingalpha.com · Mar 24
Sonova expects FY revenue at lower end of target range, CEO says in interview
reuters.com · Feb 20
Sonova Holding AG (SONVY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Nov 15
Sonova Holding AG (SONVF) Q4 2025 Earnings Call Transcript
seekingalpha.com · May 9
Sonova Shares Jump on Sales Beat, CEO Change
wsj.com · May 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.